Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13682MR)

This product GTTS-WQ13682MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13682MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10398MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ4269MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ15311MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ7894MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ2469MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 181
GTTS-WQ15037MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ11368MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ11165MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1333
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW